DOCSLIB.ORG

Product Sheet Info

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product Sheet Info Product Information Sheet for NR-19544 Salmonella enterica subsp. enterica, Strain supplemented with 15% glycerol. ® Ty2 (Serovar Typhi), Gateway Clone Set, Packaging/Storage: Recombinant in Escherichia coli, Plate 23 NR-19544 was packaged aseptically in a 96-well plate. The product is provided frozen and should be stored at -80°C or Catalog No. NR-19544 colder immediately upon arrival. For long-term storage, the This reagent is the tangible property of the U.S. Government. vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided. For research use only. Not for human use. Growth Conditions: Media: Contributor: LB broth or agar containing 50 µg/mL kanamycin. Pathogen Functional Genomics Resource Center at the J. Incubation: Craig Venter Institute Temperature: 37°C Atmosphere: Aerobic Manufacturer: Propagation: BEI Resources 1. Scrape top of frozen well with a pipette tip and streak onto agar plate. Product Description: 2. Incubate the plates at 37°C for 24 hours. Clone plates are replicated using a BioMek® FX robot. Production in the 96-well format has increased risk of cross- Citation: contamination between adjacent wells. Individual clones Acknowledgment for publications should read “The following should be purified (e.g. single colony isolation and reagent was obtained through BEI Resources, NIAID, purification using good microbiological practices) and NIH: Salmonella enterica subsp. enterica, Strain Ty2 sequence-verified prior to use. BEI Resources only confirms (Serovar Typhi), Gateway® Clone Set, Recombinant in the clone plate orientation and viability of randomly picked Escherichia coli, Plate 23, NR-19544.” clones. BEI Resources does not confirm or validate individual clone identities provided by the contributor. Biosafety Level: 1 Appropriate safety procedures should always be used with The Salmonella enterica subsp. enterica (S. enterica subsp. this material. Laboratory safety is discussed in the following ® enterica), strain Ty2 (serovar Typhi), Gateway clone set publication: U.S. Department of Health and Human Services, consists of approximately 3380 sequence validated clones Public Health Service, Centers for Disease Control and from S. enterica subsp. enterica, strain Ty2, cloned in Prevention, and National Institutes of Health. Biosafety in Escherichia coli (E. coli) DH10B-T1 cells. Each open reading Microbiological and Biomedical Laboratories. 5th ed. frame was constructed in vector pDONR221 (Invitrogen) Washington, DC: U.S. Government Printing Office, 2009; see with an ATG start codon and no stop codon. The sequence www.cdc.gov/biosafety/publications/bmbl5/index.htm. was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than Disclaimers: 0.2%. Detailed information about each clone is shown in You are authorized to use this product for research use only. Table 1. It is not intended for human use. ® Information related to the use of Gateway Clones can be Use of this product is subject to the terms and conditions of obtained from Invitrogen. Recombination was facilitated the BEI Resources Material Transfer Agreement (MTA). The through an attB substrate (attB-PCR product or a linearized MTA is available on our Web site at www.beiresources.org. attB expression clone) with an attP substrate (pDONR221) to create an attL-containing entry clone. The entry clone While BEI Resources uses reasonable efforts to include contains recombinational cloning sites, attL1 and attL2 to accurate and up-to-date information on this product sheet, facilitate gene transfer into a destination vector, M13 forward neither ATCC® nor the U.S. Government makes any and reverse priming sites for sequencing and a kanamycin warranties or representations as to its accuracy. Citations resistance gene for selection. Please refer to the Invitrogen from scientific literature and patents are provided for Gateway® Technology Manual for additional details. informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been Plate orientation and viability were confirmed for NR-19544. confirmed to be accurate. Material Provided: This product is sent with the condition that you are Each inoculated well of the 96-well plate contains responsible for its safe storage, handling, use and disposal. approximately 60 µL of E. coli culture (strain DH10B-T1) in ATCC® and the U.S. Government are not liable for any Luria Bertani (LB) broth containing 50 µg/mL kanamycin damages or injuries arising from receipt and/or use of this BEI Resources E-mail: [email protected] www.beiresources.org Tel: 800-359-7370 Fax: 703-365-2898 © 2013 American Type Culture Collection (ATCC). All rights reserved. NR-19544_20NOV2013 Page 1 of 4 Product Information Sheet for NR-19544 product. While reasonable effort is made to ensure its derivatives must contact the contributor to determine if a authenticity and reliability of materials on deposit, the U.S. license is required. U.S. Government contractors may need Government, ATCC®, their suppliers and contributors to BEI a license before first commercial sale. Resources are not liable for damages arising from the misidentification or misrepresentation of products. References: 1. Deng, W., et al. “Comparative Genomics of Salmonella Use Restrictions: enterica serovar Typhi strains Ty2 and CT18.” J. This material is distributed for internal research, non- Bacteriol. 185 (2003): 2330-2337. PubMed: 12644504. commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as ATCC® is a trademark of the American Type Culture performed under a U.S. Government contract, individuals Collection. contemplating commercial use of the material, its products or Table 1: Salmonella enterica subsp. enterica, Strain Ty2 (Serovar Typhi), Gateway® Clone Set, Recombinant in Escherichia coli, Plate 23 (ZSTDW)1 Well ORF Accession Average Depth of Clone Locus ID Description Position Length Number Coverage 92265 A01 t1643 hypothetical protein t1643 913 NP_805421.1 1.423877 92070 A02 t2206 hemolysin-like protein 913 NP_805950.1 2 92057 A03 t2341 2-hydroxy-3-oxoproprionate reductase 913 NP_806074.1 1.757941 inorganic polyphosphate/ATP-NAD 92146 A04 t2637 913 NP_806348.1 2 kinase 92274 A05 t3195 hypothetical protein t3195 913 NP_806873.1 1.702081 92289 A06 t3599 aldolase 913 NP_807242.1 2.950712 92031 A07 t1034 heat shock protein HtpX 916 NP_804852.1 2.136463 92114 A08 t1794 transcriptional regulator 916 NP_805567.1 1.959607 92199 A09 t1926 DNA methylase 916 NP_805693.1 1.449782 92017 A10 t3298 ribosomal protein L11 methyltransferase 916 NP_806973.1 1.858079 92213 A11 t3838 sugar kinase 916 NP_807459.1 1.99345 92373 A12 t0672 cytidine deaminase 919 NP_804521.1 3.972797 92033 B01 t0739 hypothetical protein t0739 919 NP_804583.1 1.570185 92354 B02 t3077 oxidoreductase 919 NP_806762.1 1.553863 92337 B03 t3199 lipoprotein Nlpl 919 NP_806877.1 1.843308 92322 B04 t3301 methyltransferase 919 NP_806976.1 1.853101 92298 B05 t3342 chloramphenicol-sensitive protein RarD 919 NP_807010.1 1.927095 92257 B06 t0954 flagellar motor protein MotA 922 NP_804778.1 1.687636 92082 B07 t2496 2-methylisocitrate lyase 922 NP_806224.1 1.801518 92157 B08 t2769 AraC family transcriptional regulator 922 NP_806470.1 2.752711 glycerol-3-phosphate transporter 92066 B09 t3965 922 NP_807575.1 1.996746 permease 92042 B10 t4176 LysR family transcriptional regulator 922 NP_807780.1 1.984816 iron-hydroxamate transporter substrate- 92349 B11 t0201 925 NP_804083.1 3.092973 binding protein peptide transport system permease 92230 B12 t1608 925 NP_805386.1 1.837838 SapC 92206 C01 t2421 protoheme IXfarnesyltransferase 925 NP_806151.1 1.548108 92105 C02 t3668 phosphate transporter permease PtsA 925 NP_807304.1 2.151351 92250 C03 t4133 maltose ABC transporter permease 925 NP_807737.1 1.502703 92162 C04 t4342 methyltransferase 925 NP_807935.1 1.972973 92293 C05 t0151 quinolinate phosphoribosyltransferase 928 NP_804034.1 1.856681 N-acetylmuramic acid-6-phosphate 92262 C06 t0286 928 NP_804162.1 1.975216 etherase 92334 C07 t2156 glycosyl transferase 928 NP_805907.1 1.794181 BEI Resources E-mail: [email protected] www.beiresources.org Tel: 800-359-7370 Fax: 703-365-2898 © 2013 American Type Culture Collection (ATCC). All rights reserved. NR-19544_20NOV2013 Page 2 of 4 Product Information Sheet for NR-19544 Well Locus ORF Accession Average Depth Clone Description Position ID Length Number of Coverage 92102 C08 t2329 carbamate kinase 928 NP_806063.1 1.883621 92381 C09 t3256 N-acetylneuraminate lyase 928 NP_806931.1 3.984914 92246 C10 t0193 glutamyl-Q tRNA(Asp) synthetase 931 NP_804076.1 1.588614 92045 C11 t1307 oxidoreductase 931 NP_805108.1 2.140709 4-hydroxyphenylacetate 3- 92190 C12 t1811 monooxygenase operon regulatory 931 NP_805584.1 1.37594 protein 92270 D01 t2676 transcriptional regulator 931 NP_806387.1 1.870032 92562 D02 t3155 LysR family transcriptional regulator 931 NP_806836.1 1.997852 92401 D03 t3558 ferrous iron efflux protein F 931 NP_807203.1 1.978518 92513 D04 t3598 oxidoreductase 931 NP_807241.1 2.452202 92741 D05 t0042 transcriptional activator NhaR 934 NP_803926.1 2.819058 92397 D06 t0407 coproporphyrinogen III oxidase 934 NP_804276.1 1.911135 92446 D07 t0563 hypothetical protein t0563 934 NP_804420.1 1.671306 92674 D08 t0776 dTDP-4-dehydrorhamnose reductase 934 NP_804618.1 1.85546 92691 D09 t0802 ATP phosphoribsyltransferase 934 NP_804644.1 1.87045 92449 D10 t1408 regulatory protein 934 NP_805203.1
Load more

Recommended publications
  • List of 246 Protein Complex Pairs Identified by DM-Align
    SUPPLEMENTARY MATERIAL Table S1: List of 246 protein complex pairs identified by DM-align. Query PDB IDa PDB Classb: Temp PDB IDd PDB Classb: TM- R(Å)f (Chain1,Chain2) GO termc (Chain1,Chain2) GO termc scoree 1djt (A,B) Toxin: Ion 1aap (A,B) Protease/Inhibitor 0.368 4.8 channel inhibitor complex: serine activity type endopeptidase activity and inhibitor 1dkf (A,B) Hormone/Growth 1xb7 (A1,A2) DNA binding and 0.849 3.1 Factor Receptor: Transcription DNA binding and factor activity transciption factor activity 1dl5 (A,B) Transferase: 1utx (A,B) DNA binding 0.437 3.9 Methyltransferas protein: Sequence e activity specific DNA binding 1dlf (L,H) Immunoglobin: 1j05 (L,H) Immunoglobin: 0.917 1.6 Antibody Antigen binding 1do5 (A,B) Chaperone: 1xso (A,B) Superoxide 0.953 0.9 Copper ion Acceptor: Copper binding activity ion binding 1dos (A,B) lyase: fructose- 1rvg (A,B) lyase: fructose- 0.760 3.6 biphosphate biphosphate aldolase aldolase 1dp4 (A,C) Hormone/Growth 1dz3 (A1,A2) Response 0.481 4.7 Factor Receptor: Regulator: DNA protein kinase binding and activity transcription factor activity 1dqp (A,B) Transferase: 1grv (A,B) Transferase: 0.856 2.9 transferring transferring glycosyl groups glycosyl groups 1dqw (A,B) Lyase: orotidin- 2jgy (A,B) Transferase: 0.95 1.7 5-phosphate orotidin-5- decarboxylase phosphate decarboxylase 1ds6 (A,B) Signalling 1cc0 (A,E) Signalling 0.897 2.2 Protein: GTPase Protein: GTPase activity activity 1dth (A,B) Hydrolase: 1sqv (A2,K2) Oxidoredutase: 0.423 2.7 Metaloendopepti Metaloendopepti dase activity dase activity 1dvf
    [Show full text]
  • Using MALDI-TOF MS Analysis for Rapid Discrimination of MRSA MLST
    Using MALDI-TOF MS analysis for rapid discrimination of MRSA MLST types Jang-Jih Lu1,2,Tsui-Ping Liu1, Shih-Cheng Chang1,2 1Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 2Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan Email: [email protected] 73 0:F8 MS Ra w 71 0:F9 MS Ra w 5000 6422.794 6000 Intens.[a.u.] Intens.[a.u.] Introduction 4000 Results ST5 ST5 4000 3000 2978.985 2000 6551.531 Staphylococcus aureus is one of the common causes of 3027.802 3054.785 2964.900 3175.943 2000 Table 1: MRSA and MSSA associated peaks by MALDI TOF 1000 community-associated infections and health care related 234 0:F1 MS Ra w 234 0:F1 MS Ra w 3005.919 MRSA(129 isolates) MSSA(77 isolates) 5000 6000 Intens.[a.u.] Intens.[a.u.] pathogen. It can usually cause wound infection, ST45 4000 ST45 6549.206 4000 3000 MS peaks (m/z) no. of isolate % of isolate no. of isolate % of isolate 6420.525 osteomyelitis, and even serious invasive infections, such as 2000 6610.628 2000 2978.373 3053.663 3174.805 2415 67 51.9 2 2.6 1000 sepsis and pneumonia. Epidemiology studies have shown 86 0:E4 MS Ra w 70 0:E5 MS Ra w 3058.565 5000 2431 65 50.4 0 0 3074.390 6000 Intens.[a.u.] Intens.[a.u.] that there are close relationship between the results of ST59 4000 6550.723 ST59 4000 3000 2879 51 39.5 2 2.6 6422.151 genotyping from multilocus sequence typing (MLST) and 2000 2000 characteristics of MRSA strains, including hospital- 6593 77 59.7 7 9.1 1000 200 0:E8 MS Ra w 38 0:E11 MS Ra w Appear of any above 103 79.8 11 14.3 2978.890 5000 6000 Intens.[a.u.] Intens.[a.u.] 6421.658 acquired, community-associated strain and even the 2965.568 ST239 4000 ST239 peaks 4000 3000 none of above peaks 6590.270 26 20.1 66 85.7 2937.113 3177.333 2916.384 antibiogram of the strain.
    [Show full text]
  • The Microbiota-Produced N-Formyl Peptide Fmlf Promotes Obesity-Induced Glucose
    Page 1 of 230 Diabetes Title: The microbiota-produced N-formyl peptide fMLF promotes obesity-induced glucose intolerance Joshua Wollam1, Matthew Riopel1, Yong-Jiang Xu1,2, Andrew M. F. Johnson1, Jachelle M. Ofrecio1, Wei Ying1, Dalila El Ouarrat1, Luisa S. Chan3, Andrew W. Han3, Nadir A. Mahmood3, Caitlin N. Ryan3, Yun Sok Lee1, Jeramie D. Watrous1,2, Mahendra D. Chordia4, Dongfeng Pan4, Mohit Jain1,2, Jerrold M. Olefsky1 * Affiliations: 1 Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA. 2 Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. 3 Second Genome, Inc., South San Francisco, California, USA. 4 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA. * Correspondence to: 858-534-2230, [email protected] Word Count: 4749 Figures: 6 Supplemental Figures: 11 Supplemental Tables: 5 1 Diabetes Publish Ahead of Print, published online April 22, 2019 Diabetes Page 2 of 230 ABSTRACT The composition of the gastrointestinal (GI) microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine (fMLF), are elevated in high fat diet (HFD)- induced obese mice. Genetic or pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon- like peptide-1 (GLP-1). Obese Fpr1-knockout (Fpr1-KO) mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota.
    [Show full text]
  • Saccharomyces Cerevisiae Aspartate Kinase Mechanism and Inhibition
    In compliance with the Canadian Privacy Legislation some supporting forms may have been removed from this dissertation. While these forms may be included in the document page count, their removal does not represent any loss of content from the dissertation. Ph.D. Thesis - D. Bareich McMaster University - Department of Biochemistry FUNGAL ASPARTATE KINASE MECHANISM AND INHIBITION By DAVID C. BAREICH, B.Sc. A Thesis Submitted to the School of Graduate Studies in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy McMaster University © Copyright by David C. Bareich, June 2003 1 Ph.D. Thesis - D. Bareich McMaster University - Department of Biochemistry FUNGAL ASPARTATE KINASE MECHANISM AND INHIBITION Ph.D. Thesis - D. Bareich McMaster University - Department of Biochemistry DOCTOR OF PHILOSOPHY (2003) McMaster University (Biochemistry) Hamilton, Ontario TITLE: Saccharomyces cerevisiae aspartate kinase mechanism and inhibition AUTHOR: David Christopher Bareich B.Sc. (University of Waterloo) SUPERVISOR: Professor Gerard D. Wright NUMBER OF PAGES: xix, 181 11 Ph.D. Thesis - D. Bareich McMaster University - Department of Biochemistry ABSTRACT Aspartate kinase (AK) from Saccharomyces cerevisiae (AKsc) catalyzes the first step in the aspartate pathway responsible for biosynthesis of L-threonine, L-isoleucine, and L-methionine in fungi. Little was known about amino acids important for AKsc substrate binding and catalysis. Hypotheses about important amino acids were tested using site directed mutagenesis to substitute these amino acids with others having different properties. Steady state kinetic parameters and pH titrations of the variant enzymes showed AKsc-K18 and H292 to be important for binding and catalysis. Little was known about how the S. cerevisiae aspartate pathway kinases, AKsc and homoserine kinase (HSKsc), catalyze the transfer of the y-phosphate from adenosine triphosphate (ATP) to L-aspartate or L-homoserine, respectively.
    [Show full text]
  • Supplementary Information
    Supplementary information (a) (b) Figure S1. Resistant (a) and sensitive (b) gene scores plotted against subsystems involved in cell regulation. The small circles represent the individual hits and the large circles represent the mean of each subsystem. Each individual score signifies the mean of 12 trials – three biological and four technical. The p-value was calculated as a two-tailed t-test and significance was determined using the Benjamini-Hochberg procedure; false discovery rate was selected to be 0.1. Plots constructed using Pathway Tools, Omics Dashboard. Figure S2. Connectivity map displaying the predicted functional associations between the silver-resistant gene hits; disconnected gene hits not shown. The thicknesses of the lines indicate the degree of confidence prediction for the given interaction, based on fusion, co-occurrence, experimental and co-expression data. Figure produced using STRING (version 10.5) and a medium confidence score (approximate probability) of 0.4. Figure S3. Connectivity map displaying the predicted functional associations between the silver-sensitive gene hits; disconnected gene hits not shown. The thicknesses of the lines indicate the degree of confidence prediction for the given interaction, based on fusion, co-occurrence, experimental and co-expression data. Figure produced using STRING (version 10.5) and a medium confidence score (approximate probability) of 0.4. Figure S4. Metabolic overview of the pathways in Escherichia coli. The pathways involved in silver-resistance are coloured according to respective normalized score. Each individual score represents the mean of 12 trials – three biological and four technical. Amino acid – upward pointing triangle, carbohydrate – square, proteins – diamond, purines – vertical ellipse, cofactor – downward pointing triangle, tRNA – tee, and other – circle.
    [Show full text]
  • Q 297 Suppl USE
    The following supplement accompanies the article Atlantic salmon raised with diets low in long-chain polyunsaturated n-3 fatty acids in freshwater have a Mycoplasma dominated gut microbiota at sea Yang Jin, Inga Leena Angell, Simen Rød Sandve, Lars Gustav Snipen, Yngvar Olsen, Knut Rudi* *Corresponding author: [email protected] Aquaculture Environment Interactions 11: 31–39 (2019) Table S1. Composition of high- and low LC-PUFA diets. Stage Fresh water Sea water Feed type High LC-PUFA Low LC-PUFA Fish oil Initial fish weight (g) 0.2 0.4 1 5 15 30 50 0.2 0.4 1 5 15 30 50 80 200 Feed size (mm) 0.6 0.9 1.3 1.7 2.2 2.8 3.5 0.6 0.9 1.3 1.7 2.2 2.8 3.5 3.5 4.9 North Atlantic fishmeal (%) 41 40 40 40 40 30 30 41 40 40 40 40 30 30 35 25 Plant meals (%) 46 45 45 42 40 49 48 46 45 45 42 40 49 48 39 46 Additives (%) 3.3 3.2 3.2 3.5 3.3 3.4 3.9 3.3 3.2 3.2 3.5 3.3 3.4 3.9 2.6 3.3 North Atlantic fish oil (%) 9.9 12 12 15 16 17 18 0 0 0 0 0 1.2 1.2 23 26 Linseed oil (%) 0 0 0 0 0 0 0 6.8 8.1 8.1 9.7 11 10 11 0 0 Palm oil (%) 0 0 0 0 0 0 0 3.2 3.8 3.8 5.4 5.9 5.8 5.9 0 0 Protein (%) 56 55 55 51 49 47 47 56 55 55 51 49 47 47 44 41 Fat (%) 16 18 18 21 22 22 22 16 18 18 21 22 22 22 28 31 EPA+DHA (% diet) 2.2 2.4 2.4 2.9 3.1 3.1 3.1 0.7 0.7 0.7 0.7 0.7 0.7 0.7 4 4.2 Table S2.
    [Show full text]
  • Product Information Sheet for NR-19577
    Product Information Sheet for NR-19577 Streptococcus pneumoniae Gateway® Packaging/Storage: Clone Set, Recombinant in Escherichia NR-19577 was packaged aseptically in a 96-well plate. The product is provided frozen and should be stored at -80°C or coli, Plate 10 colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Catalog No. NR-19577 Freeze-thaw cycles should be avoided. This reagent is the tangible property of the U.S. Government. Growth Conditions: For research use only. Not for human use. Media: LB broth containing 50 µg/mL kanamycin LB agar containing 50 µg/mL kanamycin Contributor: Incubation: Pathogen Functional Genomics Resource Center at the J. Temperature: 37°C Craig Venter Institute Atmosphere: Aerobic Propagation: Manufacturer: 1. Scrape top of frozen well with a pipette tip and streak BEI Resources onto agar plate. 2. Incubate the plates at 37°C for 18 to 24 hours. Product Description: Clone plates are replicated using a BioMek® FX robot. Citation: Production in the 96-well format has increased risk of cross- Acknowledgment for publications should read “The following contamination between adjacent wells. Individual clones reagent was obtained through BEI Resources, NIAID, NIH: should be purified (e.g. single colony isolation and Streptococcus pneumoniae Gateway® Clone Set, purification using good microbiological practices) and Recombinant in Escherichia coli, Plate 10, NR-19577.” sequence-verified prior to use. BEI Resources only confirms the clone plate orientation and viability of randomly picked Biosafety Level: 1 clones. BEI Resources does not confirm or validate Appropriate safety procedures should always be used with individual clone identities provided by the contributor.
    [Show full text]
  • Consolidated List of Up-Regulated Proteins Expressed at Different Cr (VI) Concentrations at Time Points
    Electronic Supplementary Material (ESI) for Metallomics.
    [Show full text]
  • Grasnotice 946, Lactobacillus Plantarum Strain DSM 33452
    GRAS Notice (GRN) No. 946 https://www.fda.gov/food/generally-recognized-safe-gras/ RECEIVED gras-notice-inventory JUNO 2 1020 Chr. Hansen, In -?FFICE OF FOOD ADD ITIVE SAFETY 9015 West Maple Street Milwaukee, WI 53214 - 4298 Division of Biotechnology and GRAS Notice Review U.S .A. Center for Food Safety & Applied Nutrition (HFS-255) U.S. Food & Drug Administration Phone 414 - 607 - 5700 Fax 414 - 607 - 5959 Reference: Lactobacillus plantarum DSM 33452 June 1, 2020 Dear Sir or Madam, In accordance with the Federal Register [81 Fed. Reg. 159 (17 August 2016)] issuance on Generally Recognized as Safe (GRAS) notifications (21 CFR Part 170), Chr. Hansen is pleased to submit a notice that we have concluded, through scientific procedures that Lactobacillus plantarum (L. plantarum) DSM 33452 is generally recognized as safe for use in malolactic fermentation of wine and musts and is not subject to the pre-market approval requirements. The recommendation is to inoculate the pure starter culture of L. plantarum DSM 33452 into wine or must at an inoculation level of 1.0E+07 CFU/g at the time of crushing grapes or as early as possible in the fermentation tanks. L. plantarum DSM 33452 is sensitive to alcohol concentration, so the concentration of the organism will decrease as the concentration of alcohol in the wine or must increases. Though L. plantarum DSM 33452 is safe to consume, it would be present at negligible levels, if at all, in the finished product. It should also be noted that due to recent taxonomic changes to the genus Lactobaci/lus, Lactobacillus plantarum will be known as Lactiplantibacillus plantarum moving forward (Zheng, et al., 2020).
    [Show full text]
  • Assay for Detecting Mycoplasma by Measuring Acetate Kinase Or Carbamate Kinase Activity
    (19) & (11) EP 2 264 181 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 22.12.2010 Bulletin 2010/51 C12Q 1/04 (2006.01) C12Q 1/48 (2006.01) C12Q 1/00 (2006.01) (21) Application number: 10075423.3 (22) Date of filing: 16.04.2004 (84) Designated Contracting States: • Crouch, Sharon Patricia Mary AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nottingham NG7 1DQ (GB) HU IE IT LI LU MC NL PL PT RO SE SI SK TR • Slater, Kevin John Nottingham NG7 1ED (GB) (30) Priority: 17.04.2003 GB 0308829 • Cox, Anne 17.04.2003 US 436323 P Long Eaton, Nottingham NG10 3JB (GB) (62) Document number(s) of the earlier application(s) in (74) Representative: Didmon, Mark et al accordance with Art. 76 EPC: Potter Clarkson LLP 04727944.3 / 1 613 763 Park View House 58 The Ropewalk (71) Applicant: Cambrex Bio Science Nottingham Nottingham NG1 5DD (GB) Limited Nottingham NG1 1GF (GB) Remarks: This application was filed on 13-09-2010 as a (72) Inventors: divisional application to the application mentioned • Pitt, Anthony under INID code 62. Beeston, Nottingham NG9 2BE (GB) (54) ASSAY FOR DETECTING MYCOPLASMA BY MEASURING ACETATE KINASE OR CARBAMATE KINASE ACTIVITY (57) The invention relates to a method of detecting (ii) detecting and/or measuring the activity of acetate ki- the presence of mycoplasma in a test sample comprising: nase and/or carbamate kinase in the test sample, the (i) providing a test sample; and activity being indicative of contamination by mycoplas- ma.
    [Show full text]
  • The Carbamate Kinase-Like Carbamoyl Phosphate Synthetase of The
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 12803–12808, November 1997 Biochemistry The carbamate kinase-like carbamoyl phosphate synthetase of the hyperthermophilic archaeon Pyrococcus furiosus, a missing link in the evolution of carbamoyl phosphate biosynthesis VIRGINIE DURBECQ*, CHRISTIANNE LEGRAIN†,MARTINE ROOVERS‡§,ANDRE´ PIE´RARD*†, AND NICOLAS GLANSDORFF†‡§¶ *Laboratoire de Microbiologie, Universite´Libre de Bruxelles, †Research Institute of the Centre de Recherches et d’Enseignement des Industries Alimentaires et Chimiques, ‡Microbiologie, Vrije Universiteit Brussel, and §Flanders Interuniversity Institute for Biotechnology, Avenue E. Gryson 1, B-1070 Brussels, Belgium Communicated by H. Edwin Umbarger, Purdue University, West Lafayette, IN, September 16, 1997 (received for review July 9, 1997) ABSTRACT Microbial carbamoyl phosphate synthetases protein, and it was proposed that the synthetase gene had (CPS) use glutamine as nitrogen donor and are composed of evolved by duplication of a smaller ancestral gene—possibly two subunits (or domains), one exhibiting glutaminase activ- coding for a carbamate kinase (CK) (5). CKs (EC 2.7.2.2) are ity, the other able to synthesize carbamoyl phosphate (CP) homodimers composed of subunits of 31–37 kDa (6). As from bicarbonate, ATP, and ammonia. The pseudodimeric carbamate is in chemical equilibrium with bicarbonate and 2 organization of this synthetase suggested that it has evolved by ammonia, CK can synthesize CP from HCO3 ,NH3 and one duplication of a smaller kinase, possibly a carbamate kinase molecule of ATP (Fig. 1). This evolutionary scheme found (CK). In contrast to other prokaryotes the hyperthermophilic support in the weak but nevertheless suggestive sequence archaeon Pyrococcus furiosus was found to synthesize CP by similarities that were brought to light between carB and the using ammonia and not glutamine.
    [Show full text]
  • Sigma Enzymes, Coenzymes and Enzyme Substrates
    Sigma Enzymes, Coenzymes and Enzyme Substrates Library Listing – 485 spectra This library represents a material-specific subset of the larger Sigma Biochemical Condensed Phase Library relating to enzymes, coenzymes and enzyme substrates found in the Sigma Biochemicals and Reagents catalog. Spectra acquired by Sigma-Aldrich Co. which were examined and processed at Thermo Fisher Scientific. The spectra include compound name, molecular formula, CAS (Chemical Abstract Service) registry number, and Sigma catalog number. Sigma Enzymes, Coenzymes and Enzyme Substrates Index Compound Name Index Compound Name 484 (E)-Vaccenoyl coenzyme A 298 Azo soybean flour 483 (Z)-Vaccenoyl coenzyme A 295 Azoalbumin 400 1,N6-Etheno acetyl coenzyme A, Li salt 296 Azocasein 401 1,N6-Etheno coenzyme A, Na + Li salt 297 Azocoll 397 11,14,17-Eicosatrienoyl coenzyme A 379 Behenoyl coenzyme A 396 11,14-Eicosadienoyl coenzyme A 380 Benzoyl coenzyme A, Li salt 395 11-Eicosaenoyl coenzyme A 343 Bis-(p-nitrophenyl) phosphate 321 2-(b-D-Galactosidoxy)naphthol AS-LC 344 Bis-(p-nitrophenyl) phosphate, Ca salt 394 3'-Dephosphocoenzyme A 345 Bis-(p-nitrophenyl) phosphate, Na salt 370 3-Acetylpyridine adenine dinucleotide 381 Brassidoyl coenzyme A 372 3-Acetylpyridine adenine dinucleotide 9 Carbamate kinase from streptococcus phosphate, Na salt faecalis 371 3-Acetylpyridine adenine dinucleotide, 310 Carbamyl phosphate, diammonium salt reduced form 311 Carbamyl phosphate, dilithium salt 373 3-Acetylpyridine-hypoxanthine 312 Carbamyl phosphate, disodium salt dinucleotide 10 Carbonic
    [Show full text]